形象意识强的网红和有钱人已经不是唯一的使用者。目前，每八名美国成年人中就有一人在使用司美格鲁肽一类的GLP-1药物。诺和诺德公司生产了司美格鲁肽类药物奥泽米克（用于糖尿病）和韦戈维（用于减肥）。礼来公司则推出了相似的替代品替尔泊肽。

The brokerage highlighted that there are several growth opportunities for the company going ahead including the growing CS ...

2、2024年三季报：公司自主研发的口服小分子 GLP-1 受体激动剂 HDM1002，已完成用于超重或肥胖人群的体重管理适应症II期临床研究全部入组，预计于 2024 年 10 月获得顶线结果，预计 2024年 Q4 进行 pre-III期沟通；同时已完成糖尿病适应症 II 期临床研究首例受试者入组。

Executives from Impact Analytics and Carters Inc. discuss demographic shifts, changing compositions, weight loss drugs and ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Global Partners LP (NYSE:GLP) Q3 2024 Earnings Call Transcript November 8, 2024 Global Partners LP misses on earnings ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...